Boehringer Ingelheim

Patients

At Reuters Pharma USA, editor-in-chief Jonah Comstock caught up with Brian Hilberdink, the new head of US human pharma at Boehringer Ingelheim.

Market Access

Brian Hilberdink, Boehringer Ingelheim's new Head of US Human Pharma, fielded questions on a variety of hot topics from the Reuters Pharma USA stage.

News

Boehringer's cystic fibrosis gene therapy is poised to start clinical testing, hoping to offer a one-shot alternative to costly CFTR modulator drugs.

News

Boehringer Ingelheim's oral HER2 inhibitor zongertinib has started an FDA review as a lung cancer treatment with a decision due in the third quarter.

News

Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings.

News

Boehringer Ingelheim's bid to develop the first drug therapy for impaired cognitive function in schizophrenia looks like it has reached an end.